SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sullivan KM,Monto AS,Longini IM. Estimates of the U.S. health impact of influenza. Am J Public Health. 1993; 83: 17121716.
  • 2
    Centers for Disease Control and Prevention.Key facts about influenza and the influenza vaccine. Available at URL: http://http://www.cdc.gov/flu/keyfacts.htm Accessed January 23, 2006.
  • 3
    Kempe A,Hall CB,MacDonald NE, et al. Influenza in children with cancer. J Pediatr. 1989; 115: 3339.
  • 4
    Feldman S,Webster RG,Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer. 1977; 39: 350353.
  • 5
    Elting LS,Whimbey E,Lo W,Couch R,Andreeff M,Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer. 1995; 3: 198202.
  • 6
    Cooksley CD,Avritscher EB,Bekele BN,Rolston KV,Geraci JM,Elting LS. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer. 2005; 104: 618628.
  • 7
    Centers for Disease Control and Prevention. Prevention and Control of Influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2006; 55(RR-10): 142.
  • 8
    Ring A,Marx G,Steer C,Prendiville J,Ellis P. Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. Int J Clin Pract. 2003; 57: 542543.
  • 9
    Institute of Medicine. Financing Vaccines in the 21st Century: Assuring Access and Availability. Washington, DC: National Academies Press; 2003. Available at URL: http://www.iom.edu/CMS/3809/4667/14451.aspx Accessed January 22, 2006.
  • 10
    Porter CC,Poehling KA,Hamilton R,Frangoul H,Cooper WO. Influenza immunization practices among pediatric oncologists. J Pediatr Hematol Oncol. 2003; 25: 134138.
  • 11
    Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol. 2003; 21: 11611166.
  • 12
    Surveillance, Epidemiology, and End Results (SEER) Program. Seer*Stat Database. Incidence-SEER 9 Regs Public-Use, November 2003 Submission (1973–2001). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. Available at URL: http://www. seer.cancer.gov Accessed May 31, 2005.
  • 13
    Ganz PA,Shanley JD,Cherry JD. Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer. 1978; 42: 22442247.
  • 14
    Anderson H,Petrie K,Berrisford C,Charlett A,Thatcher N,Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer. 1999; 80: 219220.
  • 15
    Nordoy T,Aaberge IS,Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol. 2002; 19: 7178.
  • 16
    Rapezzi D,Sticchi L,Racchi O,Mangerini R,Ferraris AM,Gaetani G. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol. 2003; 70: 225230.
  • 17
    Robertson JD,Nagesh K,Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000; 82: 12611265.
  • 18
    Vilar-Compte D,Cornejo P,Valle-Salinas A, et al. Influenza vaccination in patients with breast cancer: a case-series analysis. Med Sci Monit. 2006; 12: CR332CR336.
  • 19
    Beyer WE,Palache AM,Luchters G,Nauta J,Osterhaus AD. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res. 2004; 103: 125132.
  • 20
    Kilbourne ED,Arden NH. Inactivated influenza vaccines. In: OrensteinPA, editor. Vaccines.3rd ed. Philadelphia: WB Saunders Company; 1999: 531552.
  • 21
    Berard A,Bravo G. Combining studies using effect sizes and quality scores: application to bone loss in postmenopausal women. J Clin Epidemiol. 1998; 51: 801807.
  • 22
    Efron B,Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
  • 23
    Cox FM,Cobb MM,Chua WQ,McLaughlin TP,Okamoto LJ. Cost of treating influenza in emergency department and hospital settings. Am J Manag Care. 2000; 6: 205214.
  • 24
    Beck JR,Pauker SG,Gottlieb JE,Klein K,Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med. 1982; 73: 8997.
  • 25
    Arias E. United States Life Tables, 2002. Natl Vital Stat Rep. 2004; 53(6): 140.
  • 26
    Mauskopf JA,Cates SC,Griffin AD,Neighbors DM,Lamb SC,Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics. 2000; 17: 611620.
  • 27
    O'Leary JF,Fairclough DL,Jankowski MK,Weeks JC. Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making. 1995; 15: 132137.
  • 28
    U.S. Department of Labor. Bureau of Labor Statistics. Consumer Price Indexes. Available at URL: http://www.bls.gov/cpi/home.htm Accessed January 16, 2005.
  • 29
    Medical Economics Company, Inc. Drug Topic Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Medical Economics Company, Inc.; 2005.
  • 30
    U.S. Census Bureau. United States Census 2000. Summary File 3. Available at URL: www.census.gov/Press-Release/www/2002/sumfile3.html Accessed December 8, 2005.
  • 31
    U.S. Office of Technology Assessment. Cost effectiveness of influenza vaccination. Pub No. OTA H 152. Washington, DC: U.S. Government Printing Office; 1981.
  • 32
    Stiver HG,Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. CMAJ. 1978; 119: 733738.
  • 33
    Ridgway D,Wolff LJ. Active immunization of children with leukemia and other malignancies. Leuk Lymphoma. 1993; 9: 177192.
  • 34
    Allison JE,Glezen WP,Taber LH,Paredes A,Webster RG. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. Infect Dis. 1977; 136: S672S676.
  • 35
    Gross PA,Lee H,Wolff JA,Hall CB,Minnefore AB,Lazicki ME. Influenza immunization in immunosuppressed children. J Pediatr. 1978; 92: 3035.
  • 36
    Smithson WA,Siem RA,Ritts REJr, et al. Response to influenza virus vaccine in children receiving chemotherapy for malignancy. J Pediatr. 1978; 93: 632634.
  • 37
    Lange B,Shapiro SA,Waldman MT,Proctor E,Arbeter A. Antibody responses to influenza immunization of children with acute lymphoblastic leukemia. J Infect Dis. 1979; 140: 402406.
  • 38
    Sumaya CV,Williams TE,Brunell PA. Bivalent influenza vaccine in children with cancer. J Infect Dis. 1977; 136: S656S6560.
  • 39
    Wilde JA,McMillan JA,Serwint J,Butta J,O'Riordan MA,Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999; 281: 908913.
  • 40
    Campbell DS,Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med. 1997; 39: 408414.
  • 41
    Nichol KL,Lind A,Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med. 1995; 333: 889893.